iTeos Therapeutics' lead candidate, belrestotug, has shown promising response rates in lung cancer trials, which is positive news. However, the increased toxicity and skepticism due to past failures in similar approaches may offset the positive impact. The company's strong financial health with over $500M in liquid assets provides a cushion for ongoing projects, but the shelving of inupadenant and focus on belrestotug may not immediately impact stock prices. Overall, the news is mixed, leading to a neutral short-term impact on the stock price.